Novavax COVID vaccine trial participants left battling a tough decision after FDA submission delayed
Novavax recently announced that it would delay its timeline for seeking U.S. authorization for its two-dose COVID-19 vaccine. This leaves thousands of Novavax trial participants stranded when it comes to travel, events and even jobs, because they can't get a different, approved vaccine.
Leslie Moreno, WRAL multimedia journalist